Products for Research Use Only
RegisterLogin

SMU-R39

CAT: 0804-HY-175782Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-175782Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) -induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis[1].
UNSPSC
12352005
Target
NF-κB; p38 MAPK; Toll-like Receptor (TLR)
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
OC1=CC=C(N2C=NC3=C2C4=CC=CC=C4N=C3N5CCN(CC)CC5)C=C1C
Molecular Formula
C23H25N5O
Molecular Weight
387.48
References & Citations
[1]Wu P, et al. Structure-based rational design of TLR7/8 antagonists through agonist scaffold reengineering for psoriasis therapy. Eur J Med Chem. 2025 Dec 5;299:118063.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TLR7; TLR8

Related Products

CatalogName
HY-N12110-01SMU-CX1
HY-157793-01SMU-L11
HY-176192SMU-14a
HY-178391SMU-037
HY-175769SMU-V18
HY-175293SMU-C68
HY-172907SMU-1k
HY-120387SMU-B
HY-179047SMU-L11-R
HY-RS13457SMU1 Human Pre-designed siRNA Set A

Alternative Products

CatalogName
GTR19272886-01SMU-R39
T208970-01SMU-L11
GTR19264428-01SMU-C68
GTR19257765-01SMU-1k
T24809-01SMU-B
GTR18042311-01EP3 (R39) polyclonal antibody
T207268-01SMU-14a
GTR19274872-01SMU-C409
GTR19273679-01SMU-037
GTR19272985-01SMU-V18

Popular Products